Biocept -Model EGFR -Target Selector Mutation Test Kit

This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung cancer.

Most popular related searches

non-small cell lung cancer

cancer characterization

Benefits of Biocept Target Selector^™ Switch-Blocker Technology

Enrichment of cancer biomarker mutations (Del19, L858R, T790M) in a high wild-type background
Suppression of wild-type DNA amplification
Proofreading DNA Polymerase resulting in lower false positives
Avoids damaged DNA templates (such as deaminated cytosines)
Ultra-high sensitivity and specificity
Combination with Sanger sequencing for orthogonal verification of the enriched mutation
Detection of Del19, L858R, T790M as well as Wild-Type are quantitative

ctDNA Performance

Sensitivity: 0.05% mutant allele fraction -single copy detection of mutant in up to 14000 copies of wild-type DNA background
Specificity: >99%
Effective range of DNA input: 10pg-50ng DNA

FFPE DNA Performance

Eliminates need for macrodissection of FFPE tissue by enriching mutations and blocking wild-type DNA amplification
Sensitivity thresholds have been established to account for artifacts introduced by formaldehyde fixation
Mutant allele frequencies below these cut-offs are considered negative for the mutation
- Del19 cutoff: 0.17%
- L858R cutoff: 0.17%
- T790M cutoff: 2.87%
Specificity: >98.4%
Effective range of DNA input: 10pg-50ng DNA

These thresholds are provided as a guideline but every research facility/laboratory should establish their own thresholds based on their own criteria.

General Specifications

Stability: 1 year
Storage: 20°C

Biocept -Model EGFR -Target Selector Mutation Test Kit

Product Details